-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Isracann Biosciences Announces Closing of First Tranche of $0.05 Unit Private Placement
Isracann Biosciences Announces Closing of First Tranche of $0.05 Unit Private Placement
VANCOUVER, British Columbia, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the "Company") is pleased to announce that it has closed the first tranche of its previously announced non-brokered private placement. The Company issued 4,679,600 units (the "Units") at a price of $0.05 per Unit for aggregate gross proceeds of $233,980 (the "Offering").
Each Unit consists of one common share of the Company (a "Share") and one common share purchase warrant (a "Warrant"). Each Warrant entitles the holder to acquire one additional Share (a "Warrant Share") at a price of $0.055 per Warrant Share for 48 months from the date of issuance.
The Company intends to use the proceeds from the Offering toward product development and general operations.
All securities issued in connection with the Offering will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities laws ending on December 3, 2022.
The securities offered have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold absent registration or compliance with an applicable exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws.
ON BEHALF OF THE BOARD OF DIRECTORS
"Phil Floucault"
Phil Floucault
Chief Executive Officer and President
About Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF)
Isracann is a multidisciplinary cannabis focused producer and product developer with Israeli-based cannabis production farm assets and a Canadian natural health medicine development and production arm. Concurrently focused on initial retail sales in Canada and in becoming a premier cannabis producer offering low-cost domestic Israeli production, the Company aims to commercialize natural health medicines in Canada and to leverage agreements within Israel for import/export opportunities and medicinal marijuana cultivation. For more information visit: .
Contact
Empire Communications Group
+1 (604) 343-2724
info@isracann.com
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Forward-looking statements may include, without limitation, statements relating to the Company's plans or goals, the Offering and the proceeds of the Offering. The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. All forward-looking statements in this press release are made as of the date of this press release. The forward-looking statements contained herein are also subject generally to assumptions and risks and uncertainties that are described from time to time in the Company's documents filed from time to time with the Canadian Securities Exchange, the British Columbia Securities Commission, the Alberta Securities Commission, and the Ontario Securities Commission. Although Isracann believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Isracann expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
VANCOUVER, British Columbia, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the "Company") is pleased to announce that it has closed the first tranche of its previously announced non-brokered private placement. The Company issued 4,679,600 units (the "Units") at a price of $0.05 per Unit for aggregate gross proceeds of $233,980 (the "Offering").
温哥华,不列颠哥伦比亚省,2022年8月3日(环球通讯社)-Isracann Biosciences Inc.(CSE:IPOT)(XFRA:A2PT0E)(场外交易:ISCNF)(The“公司“)欣然宣布,已完成其先前公布的第一批非经纪私募。本公司已发行4,679,600个单位(”单位“)以每单位0.05美元的价格计算,总收益为233,980美元(供奉").
Each Unit consists of one common share of the Company (a "Share") and one common share purchase warrant (a "Warrant"). Each Warrant entitles the holder to acquire one additional Share (a "Warrant Share") at a price of $0.055 per Warrant Share for 48 months from the date of issuance.
每个单位由一股公司普通股组成(A)分享“)及一份普通股认购权证(a”搜查令“)。每份认股权证使持有人有权额外购入一股(A)。认股权证股份“),价格为每股认股权证0.055美元,自发行日期起计48个月。
The Company intends to use the proceeds from the Offering toward product development and general operations.
该公司打算将发行所得资金用于产品开发和一般运营。
All securities issued in connection with the Offering will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities laws ending on December 3, 2022.
根据适用的证券法,所有与此次发行相关的证券将受四个月加一天的法定持有期限制,截止日期为2022年12月3日。
The securities offered have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold absent registration or compliance with an applicable exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws.
所发行的证券没有也不会根据修订后的《1933年美国证券法》(The《美国证券法》“),或任何州证券法,在未注册或未遵守美国证券法和适用州证券法的注册要求的适用豁免的情况下,不得发行或出售。
ON BEHALF OF THE BOARD OF DIRECTORS
我代表董事会
"Phil Floucault"
《菲尔·弗洛科》
Phil Floucault
Chief Executive Officer and President
菲尔·弗洛科
首席执行官兼总裁
About Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF)
Isracann is a multidisciplinary cannabis focused producer and product developer with Israeli-based cannabis production farm assets and a Canadian natural health medicine development and production arm. Concurrently focused on initial retail sales in Canada and in becoming a premier cannabis producer offering low-cost domestic Israeli production, the Company aims to commercialize natural health medicines in Canada and to leverage agreements within Israel for import/export opportunities and medicinal marijuana cultivation. For more information visit: .
Isracann Biosciences公司简介(CSE:IPOT)(XFRA:A2PT0E)(场外交易:ISCNF)
Isracann是一家专注于多学科的大麻生产商和产品开发商,拥有以色列的大麻生产农场资产和加拿大天然保健药物开发和生产部门。该公司同时专注于加拿大的初始零售,并成为提供低成本以色列国内生产的主要大麻生产商,其目标是在加拿大将天然保健药物商业化,并利用以色列境内的协议获得进出口机会和药用大麻种植。有关更多信息,请访问:。
Contact
Empire Communications Group
+1 (604) 343-2724
info@isracann.com
联系方式
帝国通信集团
+1 (604) 343-2724
邮箱:Info@isracann.com
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Forward-looking statements may include, without limitation, statements relating to the Company's plans or goals, the Offering and the proceeds of the Offering. The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. All forward-looking statements in this press release are made as of the date of this press release. The forward-looking statements contained herein are also subject generally to assumptions and risks and uncertainties that are described from time to time in the Company's documents filed from time to time with the Canadian Securities Exchange, the British Columbia Securities Commission, the Alberta Securities Commission, and the Ontario Securities Commission. Although Isracann believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Isracann expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
前瞻性信息
本新闻稿可能包含前瞻性陈述。前瞻性陈述是指不是历史事实的陈述,一般但并非总是以“预期”、“计划”、“预期”、“相信”、“打算”、“估计”、“项目”、“可能”和类似的表述,或事件或条件“将”、“将”、“可能”、“可能”或“应该”发生。前瞻性陈述可能包括但不限于与公司的计划或目标、发售和发售收益有关的陈述。本新闻稿中包含的前瞻性陈述完全受本警告性声明的限制。本新闻稿中的所有前瞻性陈述都是在本新闻稿发布之日作出的。本文中包含的前瞻性陈述一般也会受到假设和风险及不确定因素的影响,这些假设和风险及不确定因素在公司不时提交给加拿大证券交易所、不列颠哥伦比亚省证券委员会、艾伯塔省证券委员会和安大略省证券委员会的文件中有描述。尽管Isracann认为这些前瞻性陈述中表达的预期是基于合理的假设,但这些陈述并不能保证未来的业绩,实际结果可能与前瞻性陈述中的结果大不相同。Isracann明确表示不会因新信息、未来事件或其他原因而更新或修改任何前瞻性陈述,也不承担任何义务。
The CSE does not accept responsibility for the adequacy or accuracy of this release.
CSE不对本新闻稿的充分性或准确性承担责任。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧